Alvotech盘中大涨系旧财报与监管进展延续反应，未形成新增交易催化

Alvotech (ALVO) shares soared more than 18% on Monday, building on four straight sessions of gains that followed the biosimilars company's first-half 2026 earnings release and a new licensing deal announced last week.
The Iceland-based biotechnology company, which develops biosimilar medicines through a vertically integrated platform, saw its stock reach $5.24 as of mid-afternoon trading. This was up $0.81 from the prior close. The move extended a broader recovery that has seen gains in the previous four sessions.
{"type": "symbol-chart", "props": {"ticker": "ALVO"}, "data": [{"symbol": {"id": 605444, "slug": "alvo", "name": "ALVO", "company": "Alvotech", "company_name": "Alvotech", "equity_type": "stocks", "fund_type_id": 0, "followers_count": 1757, "div_yield_type": "forward", "index_group": null, "is_bdc": false, "is_reit": false, "is_currency": false, "is_crypto": false, "is_mutual_funds": false, "is_etf": false, "is_cef": false, "is_index": false, "is_bond": false, "is_commodity": false}, "prices": {"id": 605444, "last": 5.09, "change": 0.6600000000000001, "percent_change": 14.8984, "last_time": "2026-08-24T11:00:58.000-04:00", "high": 5.09, "low": 4.71, "open": 4.81, "prev_close": 4.43, "volume": 641200.295083}, "ratings": {"quant_rating": 2.728640608785887, "sell_side_rating": 4.0, "authors_rating": 3.5}, "key_data": {"last_close_price_earnings_ratio": null, "div_rate_fwd": null, "div_rate_ttm": null, "div_yield_fwd": null, "dividend_yield": null, "short_interest_shares_outstanding": 1.292030807231053, "marketcap": 1581121500.0, "impliedmarketcap": null, "estimate_eps": 0.01947, "diluted_eps_excl_extra_itmes": -0.608094, "estimate_ffo": null, "ffo_per_share_diluted": null, "pe_ratio_fwd": 227.529532614278}}]}
Monday's advance builds on a string of positive developments beginning August 19, when Alvotech released its first-half 2026 financial results. Adjusted total revenue came in at $211.9 million, down 30.8% year-over-year from $306.1 million, while adjusted EBITDA fell to $46.9 million from $53.7 million in the same period a year earlier. Gross margin held broadly steady at 54%, and cash at period-end stood at $142.8 million, down from $172.4 million at year-end 2025.
Alongside those results, the company disclosed that FDA-related manufacturing issues behind prior Complete Response Letters for AVT05, a biosimilar to Simponi and Simponi Aria, and AVT06, a biosimilar to Eylea, have been resolved. Both biologics license applications have been resubmitted, with the FDA confirming standard six-month review timelines and decisions expected in Q4 2026. Partner Dr. Reddy's also resubmitted the AVT03 application, a biosimilar to Prolia and Xgeva.
The table below showcases the stock's daily activity over the past few days:
{"type": "table", "props": {"data": [{"date": "Aug 21, 2026", "return": "+3.75%"}, {"date": "Aug 20, 2026", "return": "+7.02%"}, {"date": "Aug 19, 2026", "return": "+1.01%"}, {"date": "Aug 18, 2026", "return": "+1.80%"}, {"date": "Aug 17, 2026", "return": "-4.32%"}, {"date": "Aug 14, 2026", "return": "-0.86%"}, {"date": "Aug 13, 2026", "return": "+2.00%"}, {"date": "Aug 12, 2026", "return": "+5.53%"}, {"date": "Aug 11, 2026", "return": "+0.80%"}, {"date": "Aug 10, 2026", "return": "-1.05%"}], "columns": [{"header": "Date", "accessor": "date", "align": "left"}, {"header": "Daily Return", "accessor": "return", "align": "right", "component": {"type": "signed-value"}}], "title": "ALVO Daily Returns"}}
On August 20, analyst Terry Chrisomalis reiterated a Hold/Neutral rating on the stock, citing missed first-half 2026 earnings and a cash runway estimated at roughly 12 months, while also acknowledging the resolved manufacturing issues behind the AVT05 and AVT06 BLA resubmissions and several targeted regulatory decisions expected in Q4 2026. Read more
Comments from the Seeking Alpha community on recent Alvotech coverage reflect a cautiously optimistic tone, with users pushing back on dilution concerns and expressing confidence in near-term revenue recovery.